Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1627-1632

  Gomberg, Stephen J ^a   Wustrack, Rosanna L ^b   Napoli, Nicola ^c   Arnaud, Claude D ^b   Black, Dennis M ^b  

^a West Oaks Orthopaedic Associates   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIFEDIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; ANAMNESIS; BONE DENSITY; CASE REPORT; CONFERENCE PAPER; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; EXERCISE; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE HEALING; HUMAN; LIMB PAIN; LIMB WEAKNESS; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; STRESS FRACTURE; VERTEBRA; VITAMIN BLOOD LEVEL;

ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; FEMORAL FRACTURES; FRACTURES, STRESS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE;

RATTUS;

EID: 79956315382     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2520     Document Type: Conference Paper

References (25)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541 (Pubitemid 26411651)
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082 (Pubitemid 29014065)
3. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
4. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS 2007 Sub-trochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349-353 (Pubitemid 46563912)
5. Cheung RK, Leung KK, Lee KC, Chow TC 2007 Sequential nontraumatic femoral shaft fractures in a patient on long term alendronate. Hong Kong Med J 13:485-489 (Pubitemid 351206686)
6. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG 2008 Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346-350 (Pubitemid 351630250)
7. Lenart BA, Lorich DG, Lane JM 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306 (Pubitemid 351439247)
8. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D 2009 Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37-44
9. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE 2009 Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 24:1736-1740
10. Capeci CM, Tejwani NC 2009 Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91:2556-2561
11. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM 2009 Association of low energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353-1362
12. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771
13. Napoli N, Novack D, Armamento-Villareal R 2010 Bisphosphonate associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int 21:705-708
14. Salminen S, Pihlajamäki H, Avikainen V, Kyrö A, Böstman O 1997 Specific features associated with femoral shaft fractures caused by low energy trauma. J Trauma 43:117-122 (Pubitemid 27334942)
15. Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I 2009 Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 24:1998-2006
16. Visekruna M, Wilson D, McKiernan FE 2008 Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948-2952
17. Abrahamsen B, Eiken P, Eastell R 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register based national cohort study. J Bone Miner Res 24:1095-1102
18. Girgis CM, Sher D, Seibel MJ 2010 Atypical fractures and bisphosphonate use. N Engl J Med 362:1848-1849
19. Das De S, Setiobudi T, Shen L, Das De S 2010 A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 92:679-686
20. Kidd LJ, Stephens AS, Kuliwaba JS, Fazzalari NL, Wu AC, Forwood MR 2010 Temporal pattern of gene expression and histology of stress fracture healing. Bone 46:369-378
21. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
22. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric properties. J Bone Miner Res 20:1244-1253 (Pubitemid 40863814)
23. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215 (Pubitemid 37152030)
24. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
25. Sloan AV, Martin JR, Li S, Li J 2010 Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 47:235-240